Correction: Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT

Erratum

Richard Hauch, Malena Hinrichs, Rebecca Ruhwald, Johanna Schrum, Stefan Rutkowski, Wilhelm Woessmann, Beate Winkler. Impact of COVID-19 related restrictions on infections in children with cancer or after hematopoietic SCT. Klin Padiatr 2023 DOI 10.1055/a-2000–5388

DOI: 10.1055/a-2000-5388

The correct title is:

Impact of COVID-19 related restrictions on infections in children with cancer or after hematopoietic SCT. Please find below the corrected Table 3

Table 3 Viral infections according to study period.

Type of virus	Pre-COVID (N=1041) n (% of type of infection)	COVID (N=420) n (% of type of infection)	P
Viruses which are typically transmitted			<0.001
Adenoviruses	56(22.6)	17(30.9)
Astroviruses	15(6.0)	1(1.8)
H. Bocavirus	10(4.0)	0(0.0)
Coronaviruses (not SARS-CoV-2)	12(4.8)	1(1.8)
H. metapneumovirus	16(6.5)	0(0.0)
H. parainfluenza viruses 1/3/4	12(4.8)	0(0.0)
Influenza virus A/B	12(4.8)	0(0.0)
Norovirus	23(9.3)	0(0.0)
Respiratory syncytial virus	6(2.4)	3*(5.5)
Rhino/Enteroviruses	78(31.5)	27(49.1)
Rotavirus	6(2.4)	1(1.8)
SARS-CoV-2	0(0.0)	5(9.1)
Sapovirus	2(0.8)	0(0.0)
Total	248(100)	55(100)
Viruses which are typically reactivated			0.03
BK virus	19(11.2)	19(21.3)
Cytomegalovirus	42(24.9)	20(22.5)
Epstein-Barr Virus	38(22.5)	16(18.0)
Herpes simplex viruses	45(26.6)	24(27.0)
H. herpesvirus 6	18(10.7)	9(10.1)
JC virus	1(0.6)	0(0.0)
Varicella zoster virus	6(3.6)	1(1.1)
Total	169(100)	89(100)

Shown are all viruses detected in the analyzed study cohort and their respective percentage of all either transmitted or reactivated infections according to study period. H.: Human. Statistical analysis by Fisher’s exact test. *all three RSV infections in COVID cohort occurred in cases in April 2020. A significant decrease of typically transmitted viral infections in COVID cohort was detected, while typically reactivated viruses increased relative to cases numbers and in relation to all detected viral infections. Multiple viruses nearly completely vanished in the COVID cohort with adenoviruses and rhino/enteroviruses being the only notable exceptions.

Table 4 Use of i. v. antibiotics according to study period.

	Pre-COVID (N=1041)	COVID (N=420)	P
# i. v. antibiotics used, mean (CI95)	2.1(2.0–2.2)	2.5(2.3–2.7)	0.003
# i. v. antibiotics escalations, mean (CI95)	0.8(0.7–0.9)	1.1(0.9–1.2)	0.005
i. v. antibiotics duration, mean (d) (CI95)	8.7(8.1–9.4)	10.8(9.5–12.0)	0.005
use of meropenem, % (CI95)	17.9(15.5–20.2)	25.7(21.5–29.9)	0.004

Shown are parameters regarding usage of intravenous (i. v.) antibiotics in all cases according to study period. #: number of. Statistical analysis for mean number of antibiotics used, escalations and duration by Welch’s t-test. Statistical analysis for use of meropenem by Fisher’s exact test. Number of i. v. antibiotics given per case, number of antibiotic escalations, overall i. v. antibiotics duration and use of meropenem significantly increased in COVID cohort.

Publication History

Article published online:
12 April 2023